-
Salix Pharmaceuticals introduces Rx topical foam to treat a form of inflammatory bowel disease
RALEIGH, N.C. — Salix Pharmaceuticals last week announced that the Food and Drug Administration has accepted for filing a new drug application for Budesonide 2 mg Rectal Foam for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.
The FDA has issued an action date of Sept. 15, 2014 under the Prescription Drug User Fee Act.